arrow_back Back to App

Doubling Funding for Sickle Cell Disease Treatment and Complication Prevention.

This Act reauthorizes and significantly expands the federal program dedicated to treating sickle cell disease and other heritable blood disorders. The key change is nearly doubling the authorized annual funding to $8.2 million for fiscal years 2025 through 2029. This ensures continued support for patients, with a stronger focus on preventing and managing severe complications of the disease.
Key points
The Sickle Cell Disease treatment program is reauthorized and receives nearly double the funding ($8.2 million annually) for 2025 through 2029.
Program focus is expanded to explicitly include the prevention and treatment of complications associated with sickle cell disease.
Funding mechanisms are made more flexible, allowing grants and cooperative agreements in addition to contracts for organizations providing care.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_735
Sponsor: Sen. Scott, Tim [R-SC]
Process start date: 2025-02-26
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_735.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-02-26.

What are the main provisions?

Key points include:

  • The Sickle Cell Disease treatment program is reauthorized and receives nearly double the funding ($8.2 million annually) for 2025 through 2029.
  • Program focus is expanded to explicitly include the prevention and treatment of complications associated with sickle cell disease.
  • Funding mechanisms are made more flexible, allowing grants and cooperative agreements in addition to contracts for organizations providing care.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Scott, Tim [R-SC].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-31.

CATEGORIES

Health